Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indications

Future Cardiology

Volumn 12, Issue 2, 2016, Pages 115-128

  Roth, Eli M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

alirocumab; ezetimibe; hypercholesterolemia; LDL C; ODYSSEY; PCSK9; SAR236553 REGN727

Indexed keywords

ALIROCUMAB; DRUG ANTIBODY; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUTRALIZING ANTIBODY; PLACEBO; MONOCLONAL ANTIBODY;

ALLERGIC REACTION; DIABETES MELLITUS; DRUG APPROVAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENERAL ALLERGIC REACTION; GUILLAIN BARRE SYNDROME; HUMAN; HYPERLIPIDEMIA; INJECTION SITE REACTION; LIVER DISEASE; MULTIPLE SCLEROSIS; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYELITIS; OPTIC NEURITIS; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; REVIEW; UNITED STATES; HYPERLIPIDEMIAS;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; HUMANS; HYPERLIPIDEMIAS;

EID: 84959894369     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.15.78     Document Type: Review

References (24)

1. US FDA. FDA approves Praluent to treat certain patients with high cholesterol. www. fda. gov
2. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59, 2344-2353 (2012).
3. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. 367, 1891-1900 (2012).
4. Stein EA, Gipe D, Bergeron J et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce lowdensity lipoprotein cholesterol in patients with or without heterozygous familial hypercholesterolemia on stable statin dose with or without ezetimibe therapy: A Phase 2 randomized controlled trial. Lancet 380, 29-36 (2012).
5. Roth EM, Taskinen MR, Ginsberg HN et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. Int. J. Cardiol. 176, 55-61 (2014).
6. Roth EM, Diller P Alirocumab for hyperlipidemia: Physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. Future Cardiol. 10(2), 183-199 (2014).
7. Sanofi Aventis. Presentations for the June 9, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. www. fda. gov
8. Sanofi Aventis. Briefing information for the June 9, 2015 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. www. fda. gov
9. US FDA. Briefing information for the June 9, 2015 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. www. fda. gov to the US FDA for alirocumab approval.
10. Kastelein JJ, Robinson JG, Farnier M et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies. Cardiovasc. Drugs Ther. 28, 281-289 (2014).
11. Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1489-1499 (2015).
12. Kastelein JJ, Ginsberg HN, Langslet G et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur. Heart J. 36(43), 2996-3003 (2015).
13. Kastelein JJ. Clinical trial update III: Pharmacology & therapy. Presented at: European Society of Cardiology Congress. London, UK 29 August-2 September (2015).
14. Kereiakes DJ, Robinson JG, Cannon CP et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am. Heart J. 169, 906-915 (2015).
15. Cannon CP, Cariou B, Blom D et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur. Heart J. 36, 1186-1194 (2015).
16. Robinson JG, Colhoun HM, Bays H et al. Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS studies. Clin. Cardiol. 37(10), 597-604 (2014).
17. Bays H, Gaudet D, Weiss R et al. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J. Clin. Endocrinol. Metab. 100(8), 3140-3148 (2015).
18. Moriarty PM, Jacobson TA, Bruckert E et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized Phase 3 trial. J. Clin. Lipidol. 8(6), 554-561 (2014).
19. Roth EM, McKenney JM. ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks. Future Cardiol. 11(1), 27-37 (2015).
20. Schwartz GG, Bessac L, Berdan LG et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am. Heart J. 168(5), 682-689 (2014).
21. Stroes E, Guyton JR, Farnier M et al. Efficacy and safety of alirocumab 150 mg and 300 mg every 4 weeks in patients with poorly controlled hypercholesterolemia: the ODYSSEY CHOICE I and CHOICE II studies. Presented at: American College of Cardiology Scientific Session 2015. CA, USA, 14-16 March (2015).
22. Praluent: highlights of prescribing information. www. regeneron. com
23. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372, 2387-2397 (2015).
24. Transcript for the June 9, 2015 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC). www. fda. gov